DV
Dividend Vision

BTAI — BioXcel Therapeutics Inc

BioXcel Therapeutics Inc (BTAI)

Total return is -99.3% over the past 8.4 years, 321.9 points behind SPY at 222.6%. Its deepest 1-year drawdown was 86.0%.

BioXcel Therapeutics Inc is a single-stock equity holding that represents a direct investment in the biopharmaceutical company rather than a diversified ETF structure. The holding does not currently offer a dividend distribution, making it unsuitable for income-focused investors seeking regular dividend payments. This structure appeals primarily to investors seeking direct equity exposure to a specialized pharmaceutical company, though it lacks the diversification benefits typical of traditional ETF funds.

BTAI key facts

Asset type
Stock
Asset class
Equity
Inception date
03/08/2018
Last close
$1.19
Market cap
$27,400,784
Average volume
2030300.0
Beta
0.273
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.77